Total Investment Management Inc. Invests $212,000 in Johnson & Johnson (NYSE:JNJ)

Total Investment Management Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,284 shares of the company’s stock, valued at approximately $212,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P raised its holdings in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the period. AMI Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares during the period. Equitable Holdings Inc. raised its holdings in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares during the period. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after buying an additional 20,528 shares during the last quarter. 68.40% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Thursday, August 31st. HSBC began coverage on shares of Johnson & Johnson in a research note on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price target on the stock. Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Finally, Barclays lowered their price objective on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research note on Friday, September 8th. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $170.65.

Insider Activity

In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider William Hait sold 14,698 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $161.43 on Friday. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $419.55 billion, a P/E ratio of 32.68, a P/E/G ratio of 3.32 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The firm has a 50-day moving average price of $166.17 and a two-hundred day moving average price of $161.67.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.59 EPS. Analysts anticipate that Johnson & Johnson will post 10.03 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.